By Sriparna Roy and Maggie Fick

(Reuters) -Eli Lilly’s Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.

The Lilly-sponsored study is the first to assess tirzepatide, the active ingredient in its blockbuster diabetes GLP-1 drug Mounjaro, in young children.

Treatment options for children with type 2 diabetes for controlling blood sugar are limited to metformin and insulin. Danish rival Novo Nordisk’s older GLP-1 drug Victoza is also approved for children who are 10 years of age and older with type 2 diabetes.

Lilly said it has submitted the new data to global regulators to support expanded use of Mounjaro for children.

The drug helped

See Full Page